Imaging predictors for treatment response to immunotherapy in gastric cancer (KINGCA Week 2026) - Oct 11, 2026 - Abstract #SP9-3; Pres time: Sep 18, 2026; 01:40 PM - 02:00 PM; Location: Room B; "Nivolumab plus chemotherapy is approved as the first-line standard care for PD-L1 positive, HER2-negative AGC patients in more than 50 countries...Several other studies assessed metabolic parameters and its association with treatment response using FDG PET-CT. Further studies investigating multilayered models combining clinical, radiomics, multibiomarker, multi parameter imaging studies currently represent the dominant approach."
IO biomarker • Tumor mutational burden • Gastric Cancer • Oncology • Solid Tumor • HER-2 • MSI • PD-L1 • TMB
|